首页> 中文期刊> 《中国医学创新》 >射频消融术联合化疗在声门型喉癌治疗中的临床观察

射频消融术联合化疗在声门型喉癌治疗中的临床观察

         

摘要

Objective:To explore the clinical value of radiofrequency ablation combined with chemotherapy in the treatment of glottic carcinoma. Method:73 cases of patients with glottic carcinoma were randomly divided into the observation group and the control group in our hospital,the control group were treated with chemotherapy,the observation group were treated with radiofrequency ablation,observed the clinical efficacy,prognosis and the incidence of adverse reactions.Result:The apoptosis rate of the observation group was(27.28±2.12)%,the clinical effective rate was 73.6%(28/38),≥Ⅲadverse reactions occur was 28.9%(11/38),the apoptosis rate of the control group was(21.42±1.87)%,the clinical effective rate was 45.7%(16/35),≥Ⅲadverse reactions occur was 60.0%(21/35),the difference between the two groups was significant(P<0.05).Conclusion:Radiofrequency ablation combined with chemotherapy can significantly improve the clinical efficacy and prognosis,it has important clinical value.%  目的:探讨射频消融术联合化疗在声门型喉癌治疗中的临床价值。方法:将本院收治的73例声门型喉癌随机分为观察组和对照组,对照组给予单纯的化疗,观察组在此基础上加用射频消融术,观察两组临床疗效、预后及不良反应发生率。结果:观察组癌细胞凋亡率为(27.28±2.12)%,临床有效率为73.6%(28/38),≥Ⅲ级不良反应发生率为28.9%(11/38),对照组癌细胞凋亡率为(21.42±1.87)%,临床有效率为45.7%(16/35),≥Ⅲ级不良反应发生率为60.0%(21/35),两组比较差异有统计学意义(P<0.05)。结论:射频消融术联合化疗能显著提高声门型喉癌的临床疗效,改善患者预后,在临床中具有重要应用价值。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号